. . . "th product developments, clinical trials, regulatory approvals, and commercial launches, commencement of clinical trial for CINGAL and ability to obtain regulatory approvals for CINGAL, existing aesthetics product???s line extensions, increases in operating expenses, including research and development and selling, general and administrative expenses, capital expenditures spending and decline in in" . . .